David Cohn

David Cohn is a gynecologic oncologist at Ohio State University with expertise in hereditary ovarian cancer and PARP inhibitor therapy in germline BRCA-mutated patients. He has contributed to research on genetic testing integration into ovarian cancer management and the clinical outcomes of olaparib maintenance in gBRCA-mutated populations. His work includes survivorship considerations for women with hereditary ovarian cancer syndromes and the implications of PARP inhibitor use across treatment lines. He is involved in cooperative group trials and NCCN ovarian cancer guidelines.